
Understand testosterone testing thresholds, morning sampling, sleep evidence and when SHBG or free testosterone may help interpret a result.

A testosterone test measures the amount of testosterone in a blood sample collected at a particular time. Total testosterone is the main measurement used in the European Association of Urology's assessment of possible testosterone deficiency. SHBG and free testosterone may help interpret certain results.
This article is for informational purposes and is not medical advice. Personal testing, diagnosis and treatment decisions belong with a qualified clinician.
The European Association of Urology (EAU) recommends repeating a total testosterone result below 12 nmol/L on at least two separate occasions before making a diagnosis or starting testosterone therapy.
This is an assessment threshold, not a complete laboratory reference range. Biologically, the number describes the concentration of testosterone measured in the sample. It does not establish a persistent deficiency by itself.
For an individual report, the useful discussion is how its stated reference interval relates to this threshold and the reason for testing. The highlighted value is one part of that conversation rather than its conclusion.
The EAU places reliable measurement at the centre of assessment. It recommends a reliable laboratory assay for total testosterone and confirmation of low results under its recommended collection conditions.
Repeat testing addresses whether the low finding is confirmed. It should not be treated as a search for whichever result feels most reassuring or most concerning. The clinical question is whether the measurements support a consistent finding when collected appropriately.
A follow-up conversation can establish how the first sample was collected and what needs confirmation. Testostra's guide to following up an unexpected low result explains where repeat measurements fit in the assessment.
The EAU specifically recommends measuring SHBG and calculating free testosterone in conditions associated with altered SHBG. These measurements may also help interpret borderline total testosterone. They add context rather than replace sound total-testosterone testing.
The guideline describes equilibrium dialysis as the most accurate method for measuring free testosterone. Calculated free testosterone using SHBG and albumin is an alternative. A useful discussion therefore includes both the free-testosterone result and how it was obtained.
The EAU cautions that the available immunoassays discussed in its guidance do not accurately estimate free testosterone. It advises against direct free-testosterone measurement with those methods. A test labelled “free testosterone” should not automatically be assumed to use the preferred method.
When several hormone results appear difficult to reconcile, understanding how SHBG fits beside total testosterone can clarify the terms. The question for a clinician is whether an additional measurement would resolve a specific uncertainty about borderline total testosterone or altered SHBG.
For adult men, the clinical assessment concerns the symptoms or signs that prompted testing. The EAU requires those findings to be compatible with testosterone deficiency alongside repeatedly low morning total testosterone.
This gives the assessment two strands: the man's clinical concerns and the confirmed laboratory finding. A numerical fluctuation does not describe the clinical presentation on its own. The clinician's task is to assess whether those strands fit together.
A useful preparation is to describe the concern in ordinary language and explain why testing was requested. Bring that description alongside the report rather than substituting the word “low” for the full history. Ask which symptoms or examination findings matter to the assessment and how they relate to the measurements.
The distinction also works in the other direction. Symptoms need clinical assessment rather than an assumption that testosterone must explain them. The EAU's approach brings symptoms and biochemical confirmation together instead of allowing either to stand alone.
The approved evidence supports attention to collection time, sleep and fasting status. Acute illness also matters to interpretation. These factors have different levels of evidence and should not be treated as interchangeable explanations for a low result.
Testosterone follows a daily rhythm, with higher levels in the morning. The EAU recommends sampling between 7 and 10 a.m. and identifies 10 a.m. as the latest acceptable time for morning collection.
The time printed on a report is therefore relevant clinical information. When discussing an initial result, asking whether collection met the recommended morning window is more useful than considering the value without its timing.
The guideline also specifies fasting collection. Together with a reliable assay, these conditions provide the framework for assessing whether low total testosterone is confirmed.
Sleep research requires a careful distinction between individual experiments and pooled findings. A secondary account of a small sleep-restriction experiment reports that 10 healthy young men had 10% to 15% lower daytime testosterone after a week of five-hour nights.
A separate summary of a meta-analysis covering 18 studies and 252 men reports a different pattern across the wider evidence. Total sleep deprivation reduced testosterone. Short-term partial sleep restriction did not produce a statistically significant pooled effect.
These findings do not establish a predictable testosterone change after an ordinary short night. Nor do they show that improving sleep will necessarily bring a low result into range. The small experiment and the pooled analysis address different sleep conditions and should not be presented as equivalent findings.
The practical discussion is to include sleep history without using it to explain away the measurement. For more context, Testostra covers the overlap between sleep concerns and hormone results.
The EAU recommends fasting total-testosterone testing. Evidence from a glucose challenge helps explain why experimental food-related findings need careful framing rather than broad claims about everyday eating.
A secondary report of a glucose-load study describes a fall in testosterone after 75 g of glucose. That is a specific experimental condition. It is not evidence that an ordinary breakfast causes the same response.
The supported takeaway is the guideline's fasting recommendation, not a rule for calculating how much a particular meal changed a result. These findings also do not establish a general effect for everyday calorie intake. If collection was not fasting, the relevant question is how the clinician wants to interpret and confirm that result.
The EAU advises avoiding testosterone measurement during acute disease. It also acknowledges that testosterone's role in acute illness remains unclear. This is not a basis for predicting a fixed change during every illness.
For a sample collected while acutely unwell, a useful question is whether the timing affects the clinician's interpretation and follow-up plan. The illness is relevant context to bring to the appointment rather than a reason to assign a diagnosis from the number.
Taken together, these inputs support a clear discussion about collection conditions. The aim is to establish when the sample was taken and whether the result needs confirmation, while leaving its clinical meaning to the assessment.
Ask your physician: “Did my sample meet morning and fasting recommendations; should the low result be confirmed on separate occasions; how do my symptoms fit; and would SHBG or a reliable free-testosterone estimate clarify the result?”
Knowing whether a report shows total testosterone or a reliable free-testosterone estimate gives a medical conversation a specific starting point, which Testostra supports through evidence-led education. Its coverage addresses confusion around SHBG and other biomarkers by explaining the terminology and evidence, while keeping individual diagnosis and treatment outside the publication's role.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.




Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra